A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Multiple Myeloma
DRUG: CC-92480|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Daratumumab|DRUG: Carfilzomib|DRUG: Elotuzumab|DRUG: Isatuximab|DRUG: Carfilzomib
Recommended Dose, Up to approximately 3 years|Recommended regimen as measured by dose-limiting toxicities, Up to approximately 3 years|Number of participants with Adverse Events (AEs), From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years|Overall response rate (ORR), Up to approximately 5 years
Time-to-response (TTR), Up to approximately 5 years|Duration of response (DOR), Up to approximately 5 years|Complete Response (CR) rate, Up to approximately 5 years|Very good partial response (VGPR) rate - Cohorts D and E, Up to approximately 5 years
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.